Columvi
Glofitamab
- Strength
- 2.5 mg/2.5mL
- Form
- Solution, Concentrate
- Class
- Bispecific CD20-directed CD3 T Cell Eng…
Genentech, Inc.
Not stocked by us — reference only
Glofitamab
Listed by Genentech, Inc.
| Dosage form | Concentrate |
|---|---|
| Route | Intravenous |
| Drug class | Bispecific CD20-directed CD3 T Cell Engager |
| Approval route | BLA — biologic licence |
| NDC code | 50242-127 |
| FDA application | BLA761309 |
| RxNorm concept | 2639786 |
| Package sizes listed | 1 |
| Marketed since | June 2023 |
Same active ingredient, different manufacturer, strength or form. Products matching on both ingredient and strength are usually interchangeable — but confirm before switching, especially with modified-release forms.
Glofitamab
Genentech, Inc.
Not stocked by us — reference only
Information only, not medical advice. Nothing on this page indicates that a medication is safe or suitable for you. Speak to a prescriber or pharmacist before starting, stopping or switching any medicine.
Please don't share card details in chat.